Intravenous thrombolytic treatment in acute ischemic stroke: Initial results in the Complejo Hospitalario Universitario de Albacete;Administración de tratamiento trombolítico intravenoso en el ictus isquémico en fase aguda: Resultados en el Complejo Hospitalario Universitario de Albacete

Revista de Neurologia

Volumn 46, Issue 1, 2008, Pages 7-12

  García García, Jorge ^a   Gracia Gil, J ^a   Sopelana Garay, D ^a   Ayo Martin O ^a   Vadillo Bermejo, A ^a   Touza, B ^b   Penalver Pardines C ^a   Zorita, M D ^a   Segura, T ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b Servicio de Emergencias 112   (Spain)

Author keywords

Intracerebral hemorrhage; Mortality; Stroke; Thrombolysis; Tissue plasminogen activator; Treatment

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMERGENCY; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MORTALITY; OBSERVATIONAL STUDY; PATIENT MONITORING; PROSPECTIVE STUDY; RANKIN SCALE; RISK FACTOR; STROKE; STROKE PATIENT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 38549146350     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4601.2007142     Document Type: Article

References (33)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
2. Wardlaw JM, Del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane Review). The Cochrane Library. Issue 4. Chichester, UK: John Wiley & Sons; 2003.
3. Horowitz SH. Thrombolytic therapy in acute stroke: neurologists, get out your hands! Arch Neurol 1998; 55: 155-7.
4. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke. 2005 Guidelines Update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-21.
5. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet 2007; 369: 275-82.
6. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-18.
7. Dávalos A, Álvarez-Sabin, Martí-Vilalta JL, Castillo J, por el Registro de Trombólisis del Grupo de Estudio de las Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Proyecto Ictus. Tratamiento intravenoso con activador del plasminógeno tisular en la isquemia cerebral aguda. Med Clin (Barc) 2003; 120: 1-5.
8. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffe E, Von Kumer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. (ECASS). JAMA 1995; 274: 1017-25.
9. Hacke W, Kaste M, Fieschi C, Von Kummer R, Dávalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998; 352: 1245-51.
10. Sopelana D, Segura T, Vadillo A, Herrera M, Hernández J, García-Muñozguren S, et al. Beneficio de la instauración de guardias de neurología de presencia física en un hospital general: experiencia en el Hospital General Universitario de Albacete. Neurologia 2007; 22: 72-7.
11. Álvarez-Sabín J, Molina C, Abilleira S, Montaner J, García F, Alijotas J. 'Stroke Code'. Shortening the delay in reperfusion treatment of acute ischemic stroke. Med Clin (Barc) 1999; 113: 481-3.
12. European Stroke Initiative (EUSI). Acute treatment of ischaemic stroke. Cerebrovasc Dis 2004; 17 (Suppl 2): S30-46.
13. Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff NM, Grotta JC. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 2000; 31: 1812-6.
14. Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST Investigators. Neurology 1993, 43: 1021-7.
15. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172: 1307-12.
16. Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE, et al. Acute stroke thrombolysis with intravenous plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-8.
17. Albers GW, Bates VE, Clark WM, Bell R,Veiro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-50.
18. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162: 1994-2001.
19. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 1151-8.
20. Mohr JP. Thrombolytic therapy for ischemic stroke: from clinical trials to clinical practice. JAMA 2000; 283: 1189-91.
21. Chapman KM, Woolfenden AR, Graeb D, Johnston DC, Beckman J, Schulzer M, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian's Hospital experience. Stroke 2000; 31: 2920-4.
22. Katzan IL, Sila CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute ischemic stroke: results of brain matters stroke management survey. Stroke 2001; 32: 861-5.
23. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or = 80 years) stroke patients. Stroke 2005; 36: 2421-5.
24. The ATLANTIS, ECASS and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
25. López-Yúñez AM, Bruno A,Williams LS,Yilmaz E, Zurrú C, Biller J. Protocol violations in community-based rt-PA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32: 12-6.
26. Dávalos A, Castillo J, Martínez-Vila E. Delay in neurological attention and stroke outcome. Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Stroke 1995; 26: 2223-7.
27. Goldstein LB, Matchar DB, Hoff-Lindquist J, Samsa GP, Horner RD. VA Stroke study: neurologist care is associated with increased testing but improved outcomes. Neurology 2003; 61: 792-6.
28. Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Álvarez-Sabín J. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004; 35: 486-90.
29. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrow AV. Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke 2003; 34: 695-8.
30. Mostacero E, Santos S, Dávalos A. Eligibility for intravenous thrombolysis in acute stroke: a multicenter prospective study [abstract]. Stroke 2001; 32: 372.
31. Martí-Fábregas J, Martí-Vilalta JL. Latencia del ingreso hospitalario en el ataque cerebral agudo. Neurologia 1999; 14: 24-33.
32. Maestre-Moreno JF, Fernández-Pérez MD,Arnaiz-Urrutia C, Mínguez A, Navarrete-Navarro P, Martínez-Bosch J. Trombólisis en el ictus: consideración inapropiada del 'período ventana' como tiempo disponible. Rev Neurol 2005; 40: 274-8.
33. Segura T, Vega G, López S, Rubio F, Castillo J. Public perception of stroke in Spain. Cerebrovasc Dis 2003; 21-6.